温阳散结汤联合免疫治疗对表皮生长因子受体突变晚期非小细胞肺癌患者临床预后的作用分析  

Effect of Wenyang Sanjie Decoction(温阳散结汤)Combined with Immunotherapy on Clinical Prognosis of Advanced Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation

作　　者：罗家江 LUO Jiajiang(Qianxinan Prefecture Traditional Chinese Medicine Hospital,Xingyi 562400,Guizhou,China)

机构地区：[1]贵州省黔西南州中医医院,贵州兴义562400

出　　处：《中华中医药学刊》2025年第3期178-181,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：国家中医药管理局项目(20172019)。

摘　　要：目的探讨温阳散结汤联合免疫治疗对表皮生长因子受体(epidermal growth factor receptor,EGFR)突变的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的临床预后效果。方法选择医院2019年1月—2023年1月收治的93例EGFR突变的NSCLC患者作为研究对象,所有患者均接受相同方案的化疗治疗,将接受免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)治疗的40例患者作为对照组,将接受温阳散结汤联合ICIs治疗的53例患者作为观察组,比较两组肿瘤反应情况、治疗前后肿瘤标志物以及生活质量,比较不良反应发生情况。结果观察组疾病控制率(disease control rate,DCR)为98.11%,客观缓解率(Objective Response Rate,ORR)为66.04%,对照组DCR为95.00%,ORR为65.00%,组间近期疗效差别无统计学意义(P>0.05);治疗后两组血清癌胚抗原(carcinoembryonic antigen,CEA)、糖类抗原125(Carbohydrate antigen 125,CA125)均明显低于治疗前(P<0.05),但组间差异无统计学意义(P>0.05);治疗后观察组口干舌燥、气短懒言、总分评分明显低于对照组(P<0.05),其余评分组间差异无统计学意义(P>0.05);观察组不良反应总发生率为32.08%,对照组为47.50%(P>0.05)。结论温阳散结汤联合免疫治疗表皮生长因子受体突变的晚期非小细胞肺癌疗效确切,对于改善中医症状效果明显,且具有较高的安全性,适合推广。Objective To investigate the clinical prognostic effect of Wenyang Sanjie Decoction(温阳散结汤)combined with immunotherapy on patients of epidermal growth factor receptor(EGFR)mutated advanced non-small cell lung cancer(NSCLC).Methods Ninety-three NSCLC patients with EGFR mutation admitted to the hospital from January 2019 to January 2023 were se-lected as study subjects,and all patients received the same chemotherapy regimen.Forty patients treated with immune checkpoint inhibitors(ICIs)were selected as the control group,and the other 53 patients treated with Wenyang Sanjie Decoction combined with ICIs were selected as the observation group.Tumor response,tumor markers and quality of life before and after treatment were compared between the two groups.The occurrence of toxic and side effects was compared.Results The disease control rate(DCR)and objective response rate(ORR)of the observation group were 98.11%and 66.04%,respectively,and those of the control group were 95.00%and 65.00%,respectively.There was no significant difference in short-term efficacy between the groups(P>0.05).After treatment,the levels of carbohydrate antigen 125(CA125)and carcinoembryonic antigen(CEA)in both groups were significantly lower than those before treatment(P<0.05),but there was no statistical significance between two groups(P>0.05).After treatment,the total score of the observation group was significantly lower than that of the control group(P<0.05),and there was no significant difference between the two groups(P>0.05).The total incidence of toxic and side effects was 32.08%in observation group and 47.50%in control group(P>0.05).Conclusion Wenyang Sanjie Decoction com-bined with immunotherapy for advanced NSCLC with EGFR mutation is effective in improving the symptoms of traditional Chinese medicine and has a high safety,suitable for promotion.

关 键 词：温阳散结汤 免疫 表皮生长因子受体 晚期非小细胞肺癌 

分 类 号：R289.5[医药卫生—方剂学] R273[医药卫生—中药学]